Kyle Rasbach is listed as a director on 2 SEC Form D filings by 2 issuers between Jul 2019 and Aug 2022: Curzion Pharmaceuticals, Inc. (San Diego, CA — pharmaceuticals — 2019; $3.5M reported sold to 8 investors) and BioSplice Therapeutics, Inc. (San Francisco, CA — pharmaceuticals — 2022).
What this means 2 separate companies raised money with this person listed as director, over about 3 years. Across those companies the filings report $3.5M sold in total.
Listed alongside Cevdet Samikoglu (1 shared filing), Darrin Beaupre (1 shared filing), Ed Mathers (1 shared filing), Erich Horsley (1 shared filing), Gur Roshwalb (1 shared filing) and 10 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kyle. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Kyle Rasbach and found 2 differences, 1 worth asking the sponsor about: Form D filed 111 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.